
Many patients with high-risk myelodysplastic syndromes miss out on effective treatment, study finds
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that underuse of these drugs may help explain why […]